Test licence, import licence, and what actually delays your trial supplies

Trial supplies are the part of start-up that teams assume will resolve itself. Approvals are tracked, contracts are tracked, the registry entry is tracked. The material arrives when it arrives.

It usually does. When it does not, the delay is rarely at customs. It is upstream, in a licence application that was started too late or scoped too narrowly, and the schedule has no slack left by the time anyone notices.

One application, one licence, and they are different forms

Import of a new drug or investigational new drug for a clinical trial, for a bioavailability or bioequivalence study, or for examination, test and analysis runs through two forms. The application is Form CT-16, made to the Central Licencing Authority under rule 67. The licence that is granted, under rule 68, is Form CT-17.

The distinction matters in correspondence. A site or a courier asking for your test licence wants the CT-17. A colleague saying the licence has been applied for is describing a CT-16. Teams lose days to this because both are called the test licence in conversation.

The validity is three years, which is longer than most people assume

A licence granted in Form CT-17 remains valid for three years from the date of issue, unless suspended or cancelled. In exceptional circumstances, where the Central Licencing Authority is satisfied about necessity and exigency, it may extend the licence by a further year on written request from the applicant.

Three years is generous relative to how these licences are treated in practice. The common failure is not expiry, it is scope: a licence obtained for one protocol, one set of sites and one quantity, then treated as though it covers the study as it subsequently changes.

The extension is worth understanding precisely because of how it is written. It is available in exceptional circumstances, on request, where the authority is satisfied about necessity and exigency. It is not a renewal that arrives because you asked in good time. A programme that expects to need a fourth year should plan for a fresh application rather than assume the extension.

The conditions are where the operational obligations sit

Rule 70 attaches conditions to the CT-17 licence, and two of them shape day to day work.

The licensee is responsible for ensuring that the new drug has been manufactured in accordance with the Act, these rules, and the principles of Good Manufacturing Practices. That is a responsibility placed on the importer, which means the manufacturing evidence has to be available to you and not merely to your supplier.

The material imported under the licence may be used only for the purposes of the clinical trial, the bioavailability or bioequivalence study, or the examination, test and analysis for which it was granted. Comparator stock imported for one study cannot be quietly redirected to another, and analytical reference material imported for testing is not trial supply.

Why the delay is usually a dependency, not a queue

The licence application is not the first step in the chain, and treating it as one is how the date slips.

The application describes what is being imported, for which protocol, and to which sites. Each of those has to be settled first. A protocol number that is still moving, a site list that is still being negotiated, or a quantity calculation that depends on an enrolment assumption nobody has fixed will all hold the application at draft. None of that is visible on a Gantt chart that shows a single bar labelled import licence.

The sequencing question is therefore not when do we apply. It is what has to be true before we can apply, and which of those things is furthest from being true today.

The other common source of delay is amendment. If sites are added after the licence is granted, the licence describes a site list that no longer matches the study. Building the likely additions into the original application costs nothing at the time and avoids an amendment cycle on the critical path.

Quantity is a regulatory decision, not a logistics one

Quantities on the application are usually produced by the supply chain team from an enrolment forecast. That is the right input and the wrong owner.

Applying for too little is the more expensive error. It puts a second application on the critical path at the exact point in the study when enrolment is going well and everyone is least willing to pause. Applying for more, with a defensible basis, does not.

The basis matters more than the number. An application that can explain how the quantity was derived, including overage for retention samples and analytical testing, answers a query before it is raised. One that cannot will be asked, and the query cycle is the delay.

What to settle before the application is drafted

The protocol number and version that the application will cite, and confirmation that it will not change before submission.

The site list, including sites you expect to add rather than only those already contracted.

The quantity, with the derivation written down: enrolment assumption, dosing, overage for retention and testing, and wastage.

Who holds responsibility for the Good Manufacturing Practices evidence, and whether you can produce it on request rather than ask your supplier to.

Whether anything in the shipment is for examination, test and analysis rather than for dosing, because the licence covers both purposes and the use restriction is enforced per purpose.

The licence is a three year instrument. The application that produces it is a two week conversation with four teams, and that conversation is the thing worth starting early.